

Applicant: Walter P. Carney et al.
Serial No.: 08/321,179
Filed: October 11, 1994
Page 2

In the Specification:

On page 1, lines 7-11, please replace "This application is a continuation-in-part of U.S.S.N. 07/297,188, filed on January 13, 1989 which is a continuation-in-part of U.S.S.N. 07/182,501, filed on April 18, 1988, which is a continuation-in-part of U.S.S.N. 06/871,102, filed on June 4, 1986." with

a1
--This application is a divisional of U.S. Serial No. 07/806,112, filed December 12, 1991 which was a continuation of U.S. Serial No. 07/412,668, filed September 29, 1989, now abandoned, which was a continuation-in-part of U.S. Serial No. 07/297,188, filed January 13, 1989, now abandoned, which was a continuation-in-part of U.S. Serial No. 07/182,501, filed April 18, 1988, now abandoned, which was a continuation-in-part of U.S. Serial No. 06/871,102, filed June 4, 1986 now U.S. Patent No. 4,935,431, issued January 19, 1990.--

REMARKS

Claims 1-18 are pending in the subject application and claims 1-2 are under examination in the subject application.

Applicants maintain the amendment to the specification raises no issue of new matter but merely updates the status of co-pending applications.

Applicants' election with traverse of Group I (claims 1 and 2) in Paper No. 2 is acknowledged by Examiner. The Examiner stated that the traversal is on the ground(s) that "the p100 peptide and the monoclonal antibodies to neu are used such related matters that